San Bernardino Sun

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Topics Government

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?

January 05, 2026

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.

Via StockStory

Topics Stocks

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗

December 22, 2025

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today ↗

Topics Government

3 Cash-Flow Machines Investors May Want Heading Into 2026 ↗

January 02, 2026

Via MarketBeat

January 01, 2026

Via Benzinga

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value

December 31, 2025

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What's Driving the Market Sentiment Around Gilead Sciences Inc? ↗

December 31, 2025

Via Benzinga

Stock Index Futures Slip in Weak End to a Banner Year

December 31, 2025

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of...

Via Barchart.com

Topics Bonds Government Stocks

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

GILEAD SCIENCES INC (NASDAQ:GILD) Shows High Technical and Setup Ratings for a Potential Breakout ↗

December 27, 2025

Gilead Sciences (GILD) shows strong technicals and a high-quality setup, suggesting a potential breakout from a tight trading range for chart-focused investors.

Via Chartmill

Jobless Claims Unexpectedly Fall For Second Consecutive Week ↗

December 24, 2025

According to data released by the U.S. Department of Labor on Wednesday, jobless claims fell by 10,000 to 214,000 in the week ended December 20.

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Topics Stocks

Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million ↗

December 24, 2025

Via Benzinga

RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug ↗

December 24, 2025

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

December 23, 2025

Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.

Topics Government

These S&P500 stocks are moving in today's session ↗

December 23, 2025

Via Chartmill

Gilead Sciences to Present at Upcoming Investor Conference

December 22, 2025

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes ↗

December 22, 2025

Via Benzinga

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 22, 2025

Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal ↗

December 20, 2025

Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.

Via Benzinga

Topics Government

Why Gilead Sciences (GILD) Stock Is Up Today

December 19, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive...

Via StockStory

Topics Earnings

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Topics Government World Trade

Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗

December 19, 2025

Via Investor's Business Daily

Topics Government Stocks

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

December 19, 2025

Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income ↗

December 19, 2025

Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts.

Via Chartmill

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Topics Economy Government

December 18, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.